Extended interval dosing of natalizumab in multiple sclerosis
Extended interval dosing of natalizumab in multiple sclerosis
About this item
Full title
Author / Creator
Zhovtis Ryerson, L , Frohman, T C , Foley, J , Kister, I , Weinstock-Guttman, B , Tornatore, C , Pandey, K , Donnelly, S , Pawate, S , Bomprezzi, R , Smith, D , Kolb, C , Qureshi, S , Okuda, D , Kalina, J , Rimler, Z , Green, R , Monson, N , Hoyt, T , Bradshaw, M , Fallon, J , Chamot, E , Bucello, M , Beh, S , Cutter, G , Major, E , Herbert, J and Frohman, E M
Publisher
England: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
BackgroundNatalizumab (NTZ), a monoclonal antibody to human α4β1/β7 integrin, is an effective therapy for multiple sclerosis (MS), albeit associated with progressive multifocal leukoencephalopathy (PML). Clinicians have been extending the dose of infusions with a hypothesis of reducing PML risk. The aim of the study is to evaluate the clinical cons...
Alternative Titles
Full title
Extended interval dosing of natalizumab in multiple sclerosis
Authors, Artists and Contributors
Author / Creator
Frohman, T C
Foley, J
Kister, I
Weinstock-Guttman, B
Tornatore, C
Pandey, K
Donnelly, S
Pawate, S
Bomprezzi, R
Smith, D
Kolb, C
Qureshi, S
Okuda, D
Kalina, J
Rimler, Z
Green, R
Monson, N
Hoyt, T
Bradshaw, M
Fallon, J
Chamot, E
Bucello, M
Beh, S
Cutter, G
Major, E
Herbert, J
Frohman, E M
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1808659674
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1808659674
Other Identifiers
ISSN
0022-3050
E-ISSN
1468-330X
DOI
10.1136/jnnp-2015-312940
